Riskpilot← Back to searchSign inGet full accessNYFB Consulting AB
ABActiveOrg 5566535554Urdavägen 15 AMedical specialists activities · NACE 8622Est. 20040 employees
Revenue 2025
SEK 149K
-71% vs 2024
EBITDA margin
-25.3%
-110% vs 2024
Equity ratio
51.1%
Financial strength
Net profit 2025
SEK -165K
-218% vs 2024
| Revenue | SEK 149K | -71% |
| EBITDA | SEK -38K | -110% |
| Net profit | SEK -165K | -218% |
| Total assets | SEK 563K | -23% |
| Equity | SEK 288K | -36% |
| Employees | 0 | — |
Legal name
NYFB Consulting AB
Org number
5566535554
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
9 januari 2004
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva utbildning och konsultverksamhet inom verksamhetsutveckling samt cancerforskning. Utöver det även skönhetsbehandlingar, framförallt föryngringsbehandling av legitimerad personal och försäljning av behandlingsrelaterade produkter. Bolaget skall även bedriva skotersafari genom organiserad turistverksamhet. Bolaget skall även bedriva konsultation inom företagsorganisation, arbetsprocesser och produktionsflöden.
Address
Urdavägen 15 A
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 046 | 673 | 163 | 509 | 149 |
| Staff expenses | — | −668 | −0 | −0 | −0 |
| EBITDA | 286 | −88 | 84 | 379 | −38 |
| Depreciation & amort. | −11 | −19 | −39 | −112 | −112 |
| EBIT | 275 | −107 | 45 | 267 | −150 |
| Net financials | −4 | −157 | −66 | −85 | −15 |
| Profit before tax | 273 | −264 | −21 | 183 | −165 |
| Tax | −57 | — | — | −43 | — |
| Net profit | 216 | −264 | −21 | 140 | −165 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 853 | 611 | 950 | 732 | 563 |
| Equity | 599 | 334 | 313 | 453 | 288 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 254 | 277 | 637 | 279 | 275 |
| Total debt | 254 | 277 | 637 | 279 | 275 |
EBITDA margin
-25.3%
This company
15.8%
Market median
-260% vs market
20212025
Equity ratio
51.1%
This company
38.2%
Market median
+34% vs market
20212025
Return on equity
-57.2%
This company
18.4%
Market median
-411% vs market
20212025
Net profit margin
-110.6%
This company
8.1%
Market median
-1465% vs market
20212025
Asset turnover
0.26×
This company
1.12×
Market median
-77% vs market
20212025
Debt / equity
0.96×
This company
0.62×
Market median
+55% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NYFB Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Lars Martin Ramqvist | Board of Directors | 0 companies |
| Eva Andrea Darai Ramqvist | Deputy Board Member | 0 companies |